Orthofix Medical (NASDAQ:OFIX) Trading Down 5.8% After Earnings Miss

Orthofix Medical Inc. (NASDAQ:OFIX) dropped 5.8% during trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $12.39 and last traded at $12.7950. Approximately 185,213 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of 223,713 shares. The stock had previously closed at $13.59.

The medical device company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.44 by ($0.50). The company had revenue of $219.91 million during the quarter, compared to analyst estimates of $218.72 million. Orthofix Medical had a negative net margin of 14.56% and a negative return on equity of 25.59%.

Key Headlines Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Company reaffirmed a multi‑year growth pathway by extending its target sales CAGR of 6.5%–7.5% through 2028 as channel optimization continues to mature — a signal that management still expects sustainable revenue growth over the medium term. Orthofix extends timeline for 6.5%-7.5% sales CAGR through 2028
• Neutral Sentiment: Q4 revenue was roughly in line with expectations (about $219.9M), indicating top‑line stability despite EPS weakness; investors should watch margin and cost commentary from the call for signs of recovery. Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Company posted slide deck and earnings‑call materials; read the presentation and call transcript for management’s detail on channel optimization and cost actions. Orthofix Q4 results – earnings call presentation
• Negative Sentiment: Reported Q4 EPS missed consensus by a wide margin (company results came in below the expected ~$0.44 consensus), producing headline disappointment and pressure on near‑term sentiment. Orthofix (OFIX) Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: FY‑2026 revenue guidance of $850M–$860M was issued and sits slightly below street consensus (~$861.4M), which can weigh on the stock as investors reassess near‑term growth. Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results
• Negative Sentiment: Company noted it excluded the impact of discontinuing its M6™ product lines from pro forma measures — the discontinuation and any associated charges or margin impacts are a near‑term headwind that investors will scrutinize. Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd. Barrington Research reiterated an “outperform” rating and set a $18.00 price target on shares of Orthofix Medical in a report on Tuesday, February 17th. Finally, TD Cowen started coverage on shares of Orthofix Medical in a report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.00.

Insider Buying and Selling

In related news, CEO Massimo Calafiore sold 9,797 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37. Following the sale, the chief executive officer owned 217,237 shares in the company, valued at $3,304,174.77. The trade was a 4.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Julie Andrews sold 4,873 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $14.38, for a total value of $70,073.74. Following the completion of the transaction, the chief financial officer directly owned 58,039 shares of the company’s stock, valued at approximately $834,600.82. The trade was a 7.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 24,270 shares of company stock worth $370,958. 1.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors have recently added to or reduced their stakes in OFIX. AQR Capital Management LLC raised its stake in shares of Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock valued at $333,000 after acquiring an additional 8,241 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after acquiring an additional 1,213 shares during the period. Jane Street Group LLC bought a new stake in Orthofix Medical in the first quarter valued at approximately $1,076,000. Strs Ohio acquired a new stake in shares of Orthofix Medical during the first quarter worth $150,000. Finally, AlphaQuest LLC lifted its holdings in Orthofix Medical by 18.4% in the second quarter. AlphaQuest LLC now owns 29,827 shares of the medical device company’s stock valued at $333,000 after buying an additional 4,625 shares during the period. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Stock Down 6.2%

The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39. The stock’s 50-day simple moving average is $14.22 and its 200 day simple moving average is $14.72. The firm has a market cap of $504.90 million, a P/E ratio of -4.21 and a beta of 0.78.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.